New Hepatitis C Treatment
– What you need to know
Thursday 30th July, 2015
Treatment for hepatitis C in Australia is set to change with new medicines to become available soon. To find out what this means for you please attend the New Hepatitis C Treatment – What you need to know webcast
Never Registered?
*Email Address
Which Australian State or Territory do you live in?
Which of the following best describes you?
Email addresses provided for the purpose of viewing this webcast will not be used for any other unsolicited purposes.
Professor Gregory Dore
Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years. He has been involved in many hepatitis C clinical trials, including with interferon-free direct acting regimens, and is an international leader in evaluation of these regimens among people who inject drugs.

He has published over 250 peer-reviewed publications and is editor of two books on hepatitis C. Professor Dore’s leadership in clinical practice and research is demonstrated through his recent Presidency of the Australasian Society for HIV Medicine (ASHM), current membership of NHMRC Council, and position as a NHMRC Practitioner Fellow.
Kevin Marriott
Kevin has been working in the blood borne viruses, community sector for 20 years. He has previously worked in Tasmania and Queensland and is currently the Policy Officer with Hepatitis Australia. Kevin has recently been responsible for national submissions to the Australia Government including the Pharmaceutical Benefits Advisory Committee, Therapeutic Goods Authority and the Parliamentary Inquiry into Hepatitis C in Australia.
Powered by Redback Webcasts - For technical assistance call: 1800 733 416
Copyright © 2015 all rights reserved.